philipn authored on Feb. 18, 2021, 1:11 a.m. | | Additions are marked like this |
Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic. Mechanism of potential benefitDipyridamole is said to "[have the] potential to inhibit multiple processes that have been recently linked to COVID-19 severity," such as purinergic signaling (related to inflammation and thrombosis), and may help induction of type 1 IFNs. Dipyridamole has also been shown to have direct anti-viral effects against SARS-CoV-2, showing anti-SARS-CoV-2 activity in vitro in Vero cells. Dipyridamole's anti-SARS-CoV-2 activity may occur via binding to the SARS-CoV-2 protease Mpro (see Fig. 1B). Research overviews:
Clinical trialsA list of clinical trials of dipyridamole for COVID-19:
See also |
Dipyridamole, a vasodilator and antiplatelet drug, has been proposed as a possible COVID-19 therapeutic. Mechanism of potential benefitDipyridamole is said to "[have the] potential to inhibit multiple processes that have been recently linked to COVID-19 severity," such as purinergic signaling (related to inflammation and thrombosis), and may help induction of type 1 IFNs. Dipyridamole has also been shown to have direct anti-viral effects against SARS-CoV-2, showing anti-SARS-CoV-2 activity in vitro in Vero cells. Dipyridamole's anti-SARS-CoV-2 activity may occur via binding to the SARS-CoV-2 protease Mpro (see Fig. 1B). Research overviews:
Clinical trialsA list of clinical trials of dipyridamole for COVID-19:
Trial results:A proof-of-concept trial of 31 COVID-19 patients was carried out in China in early 2020, finding signs of potential benefit. See also |
